Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (NCT07220811) titled 'Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy' on Oct. 22.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: RAPT Therapeutics, Inc.
Condition:
Ig-E Mediated Food Allergy
Intervention:
Drug: RPT904
Drug: RPT904
Other: Placebo
Drug: RPT904
Drug: RPT904
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: October 2025
Target Sample Size: 100
Countries of Recruitment:
United States
To kno...